Tags

Type your tag names separated by a space and hit enter

[Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Schweiz Med Wochenschr 1989; 119(10):299-305SM

Abstract

Treatment of tuberculosis should be as short and as simple as possible in order to improve patient compliance; and combinations of at least three drugs should be used in order to kill the different populations of mycobacteria and to avoid development of drug resistance.--In a controlled multicentre study two regimens were compared in 93 patients with newly-diagnosed pulmonary tuberculosis: 1) Six-month therapy (47 cases): Daily rifampicin and isoniazid, supplemented with pyrazinamide for the first 2 months. A tablet with a fixed combination of 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide (Rifater) was used. 2) Present Swiss standard therapy (46 cases): Daily rifampicin, isoniazid and ethambutol for 2 months followed by rifampicin and isoniazid for 7 months.--The time-course of culture negativation and the frequency of adverse events were similar in the two groups. During a follow-up period of at least two years only one relapse was observed in the six-month regimen, 3 months after completion of treatment. This was one of three patients with pretreatment resistance to isoniazid. Nevertheless, two of them were cured with the six-month regimen containing Rifater.--Patient compliance, assessed during outpatient treatment by detecting isoniazid metabolites in the urine, was very good (93% of tests were positive in each group).--These results with a follow-up of more than 2 years, indicate that short-course therapy of 6 months duration with the fixed combination tablet may be recommended as treatment of choice in pulmonary tuberculosis except in cases of isoniazid resistance and other special situations (i.e. large cavitations, large number of viable bacilli).

Authors+Show Affiliations

Zürcher Höhenklinik Wald, Faltigberg.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Clinical Trial
Comparative Study
Controlled Clinical Trial
English Abstract
Journal Article
Multicenter Study

Language

ger

PubMed ID

2652281

Citation

Brändli, O, et al. "[Short-term Therapy of Lung Tuberculosis Using a Fixed Combination of Isoniazid, Rifampicin and Pyrazinamide. Results After 2 Years]." Schweizerische Medizinische Wochenschrift, vol. 119, no. 10, 1989, pp. 299-305.
Brändli O, Haegi V, Villiger B, et al. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years]. Schweiz Med Wochenschr. 1989;119(10):299-305.
Brändli, O., Haegi, V., Villiger, B., Bohn, W., Baumann, H. R., & Zäch, R. (1989). [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years]. Schweizerische Medizinische Wochenschrift, 119(10), pp. 299-305.
Brändli O, et al. [Short-term Therapy of Lung Tuberculosis Using a Fixed Combination of Isoniazid, Rifampicin and Pyrazinamide. Results After 2 Years]. Schweiz Med Wochenschr. 1989 Mar 11;119(10):299-305. PubMed PMID: 2652281.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years]. AU - Brändli,O, AU - Haegi,V, AU - Villiger,B, AU - Bohn,W, AU - Baumann,H R, AU - Zäch,R, PY - 1989/3/11/pubmed PY - 1989/3/11/medline PY - 1989/3/11/entrez SP - 299 EP - 305 JF - Schweizerische medizinische Wochenschrift JO - Schweiz Med Wochenschr VL - 119 IS - 10 N2 - Treatment of tuberculosis should be as short and as simple as possible in order to improve patient compliance; and combinations of at least three drugs should be used in order to kill the different populations of mycobacteria and to avoid development of drug resistance.--In a controlled multicentre study two regimens were compared in 93 patients with newly-diagnosed pulmonary tuberculosis: 1) Six-month therapy (47 cases): Daily rifampicin and isoniazid, supplemented with pyrazinamide for the first 2 months. A tablet with a fixed combination of 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide (Rifater) was used. 2) Present Swiss standard therapy (46 cases): Daily rifampicin, isoniazid and ethambutol for 2 months followed by rifampicin and isoniazid for 7 months.--The time-course of culture negativation and the frequency of adverse events were similar in the two groups. During a follow-up period of at least two years only one relapse was observed in the six-month regimen, 3 months after completion of treatment. This was one of three patients with pretreatment resistance to isoniazid. Nevertheless, two of them were cured with the six-month regimen containing Rifater.--Patient compliance, assessed during outpatient treatment by detecting isoniazid metabolites in the urine, was very good (93% of tests were positive in each group).--These results with a follow-up of more than 2 years, indicate that short-course therapy of 6 months duration with the fixed combination tablet may be recommended as treatment of choice in pulmonary tuberculosis except in cases of isoniazid resistance and other special situations (i.e. large cavitations, large number of viable bacilli). SN - 0036-7672 UR - https://www.unboundmedicine.com/medline/citation/2652281/[Short_term_therapy_of_lung_tuberculosis_using_a_fixed_combination_of_isoniazid_rifampicin_and_pyrazinamide__Results_after_2_years]_ L2 - http://www.diseaseinfosearch.org/result/7252 DB - PRIME DP - Unbound Medicine ER -